SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Open-market buys and sells only — the deliberate trades. Zero here doesn’t mean no filings: grants, option exercises and tax withholding (below) are compensation, not market trades.
| Insider | Role | Date | Transaction | Shares | Value |
|---|---|---|---|---|---|
| Minor Lloyd | Director | 2026-08-04 | Open-market sell 10b5-1 | 593 | $119K |
| Minor Lloyd | Director | 2026-08-03 | Open-market sell 10b5-1 | 593 | $121K |
| Freire Maria C | Director | 2026-06-09 | Grant/award | 2005 | $0 |
| HAWKINS WILLIAM A | Director | 2026-06-09 | Grant/award | 1505 | $0 |
| LANGER SUSAN | Director | 2026-06-09 | Grant/award | 1505 | $0 |
| Mantas Jesus B | Director | 2026-06-09 | Grant/award | 1505 | $0 |
| Minor Lloyd | Director | 2026-06-09 | Grant/award | 1505 | $0 |
| Pangalos Menelas N | Director | 2026-06-09 | Option exercise | 2370 | $0 |
| Pangalos Menelas N | Director | 2026-06-09 | Grant/award | 1505 | $0 |
| Patolawala Monish D | Director | 2026-06-09 | Grant/award | 1505 | $0 |
| Rowinsky Eric K | Director | 2026-06-09 | Grant/award | 1505 | $0 |
| SHERWIN STEPHEN A | Director | 2026-06-09 | Grant/award | 1505 | $0 |
| Keeney Adam | Head of Corporate Development | 2026-05-01 | Option exercise | 939 | $0 |
| Keeney Adam | Head of Corporate Development | 2026-05-01 | Tax withholding | 455 | $85K |
| Godbout Sean | Chief Accounting Officer | 2026-04-01 | Option exercise | 181 | $0 |
| Godbout Sean | Chief Accounting Officer | 2026-04-01 | Tax withholding | 54 | $10K |
| Murphy Nicole | Head of Pharm Ops and Tech | 2026-02-12 | Open-market buy | 3 | $585 |
| Singhal Priya | Head of Development | 2026-02-09 | Open-market sell 10b5-1 | 2660 | $532K |
| ALEXANDER SUSAN H | EVP Chief Legal Officer | 2026-02-06 | Option exercise | 2190 | $0 |
| ALEXANDER SUSAN H | EVP Chief Legal Officer | 2026-02-06 | Tax withholding | 1059 | $213K |
Fiscal period ending 2025-12-31 versus 2024-12-31 — view filing on EDGAR →
Regulatory pressure is the dominant new risk, with the OBBBA and MFN pricing policy now explicitly flagged as material adverse threats — a meaningful escalation from prior generic tax-deal language — while IRA-driven Medicare pricing concerns add a quantified dimension. Simultaneously, customer concentration has worsened materially, with two distributors now controlling nearly 44% of gross product revenue, up from 39%, compressing the company's negotiating position.
2 company-specific · 1 common-mode
New disclosure of OBBBA, MFN pricing policy, and executive orders with material potential impact on business. Specific quantified concern about IRA's adverse impact on Medicare-reliant products.
Our results of operations may be adversely affected by current and potential future healthcare reforms including those contained in the PPACA, IRA, OBBBA, MFN and executive orders. In the U.S.…
Customer concentration risk increased materially: two distributors' combined share rose from 39.3% to 43.9% of gross product revenue, indicating heightened dependency and negotiating leverage risk.
Product Indication Major Markets Non-Hodgkin's lymphoma CLL Rheumatoid arthritis Two forms of ANCA-associated vasculitis Pemphigus vulgaris U.S. Non-Hodgkin's lymphoma CLL U.S. In combination with…
New explicit disclosure of OBBBA impact with material adverse effect language; prior year referenced only generic Global Tax Deal. Escalated specificity and risk acknowledgment.
General Risk Factors Our effective tax rate fluctuates, and we may incur obligations in tax jurisdictions in excess of accrued amounts in our financial statements. As a global company, we are subject…
Biogen issued a press release on July 29, 2026 announcing its second quarter 2026 financial results, including total revenue of $2.7 billion (up 3% year-over-year), GAAP diluted EPS of $0.66, and Non-GAAP diluted EPS of $3.60. The disclosure includes detailed revenue breakdowns by product and segment, expense summaries, cash flow information, and updated full-year 2026 guidance. This is a standard quarterly earnings release furnished under Item 2.02 of Form 8-K.
View raw filing on EDGAR →Biogen discloses preliminary unaudited financial results for Q2 2026 and provides guidance for Q3 2026, including specific charges ($164M for Q2, $290-320M for Q3) and their impact on GAAP and non-GAAP earnings per share ($0.95 and $1.75-1.95 respectively). While the disclosure focuses on acquired in-process R&D and milestone expenses rather than comprehensive earnings, it constitutes a material financial results disclosure under Item 2.02 that would affect investor assessment of quarterly performance.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the final voting results from Biogen's June 9, 2026 Annual Meeting of Stockholders. The filing presents detailed vote tallies for three matters: election of ten directors, ratification of PricewaterhouseCoopers LLP as independent auditor, and advisory approval of executive compensation. These are routine but material shareholder governance matters that affect investor understanding of board composition and corporate oversight.
View raw filing on EDGAR →